Targeted protein degradation: advances in drug discovery and clinical practice [0.03%]
靶向蛋白降解：药物发现和临床实践的进展
Guangcai Zhong,Xiaoyu Chang,Weilin Xie et al.
Guangcai Zhong et al.
Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in disease management, providing a stark contrast to traditional therapeutic approaches like small molecule inhibitors that primarily focus on inhibiting pro...
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors [0.03%]
SY-5007治疗RET变异的晚期实体瘤首次人体I期剂量递增和扩展研究
Wei Li,Yongsheng Wang,Anwen Xiong et al.
Wei Li et al.
Oncogenic RET alteration is an important, tissue-agnostic therapeutic target across diverse cancers. We conducted a first-in-human phase 1 study on SY-5007, a potent and selective RET inhibitor, in patients with RET-altered solid tumors. Pr...
Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1 [0.03%]
人脂肪间充质干细胞和脐带间充质干细胞来源的细胞外囊泡通过TIMP1 / Notch1途径缓解光老化作用机制研究
Huan Zhang,Xian Xiao,Liping Wang et al.
Huan Zhang et al.
UVB radiation induces oxidative stress, DNA damage, and inflammation, leading to skin wrinkling, compromised barrier function, and an increased risk of carcinogenesis. Addressing or preventing photoaging may offer a promising therapeutic av...
Miniproteins may have a big impact: new therapeutics for autoimmune diseases and beyond [0.03%]
小小的蛋白可能发挥大大的作用：自身免疫病及其它疾病的新型疗法
Nariaki Asada,Christian F Krebs,Ulf Panzer
Nariaki Asada
Florian R Greten,Melek C Arkan
Florian R Greten
Mapping Alzheimer's disease: exploring cellular vulnerability and resilience [0.03%]
阿尔茨海默病的细胞脆弱性和恢复力研究映射图谱
Natalia Ortí-Casañ,John R Bethea,Ulrich L M Eisel
Natalia Ortí-Casañ
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial) [0.03%]
围手术期斯鲁利单抗联合新辅助安罗替尼和化疗治疗可切除的非小细胞肺癌：一项多中心、开放性、单组、Ⅱ期TD-NeoFOUR试验
Hongtao Duan,Changjian Shao,Zhilin Luo et al.
Hongtao Duan et al.
This open-label, single-arm, phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy, followed by adjuvant sintilimab, for resectable NSCLC. Forty-five patients received anlotinib (...
Dharmendra Kumar,Iqbal Hyder,Wilfried A Kues
Dharmendra Kumar
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB [0.03%]
通过下调c-Fos和JunB防止CAR-T细胞耗竭和分化以抑制MEK信号转导
Xiujian Wang,Xiao Tao,Pengjie Chen et al.
Xiujian Wang et al.
Clinical evidence supports the notion that T cell exhaustion and terminal differentiation pose challenges to the persistence and effectiveness of chimeric antigen receptor-T (CAR-T) cells. MEK1/2 inhibitors (MEKIs), widely used in cancer tr...
Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial [0.03%]
鲁索利替尼联合类固醇治疗急性移植物抗宿主病的多中心随机三期临床试验
Liping Dou,Yanli Zhao,Jingjing Yang et al.
Liping Dou et al.
Newly diagnosed patients with high-risk acute graft-versus-host disease (aGVHD) often experience poor clinical outcomes and low complete remission rates. Ruxolitinib with corticosteroids showed promising efficacy in improving response and f...